MedPath
HSA Approval

TECENTRIQ SOLUTION FOR INJECTION 1875MG/15ML

SIN17033P

TECENTRIQ SOLUTION FOR INJECTION 1875MG/15ML

TECENTRIQ SOLUTION FOR INJECTION 1875MG/15ML

June 27, 2024

ROCHE SINGAPORE PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantROCHE SINGAPORE PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INJECTION, SOLUTION

SUBCUTANEOUS

Medical Information

L01FF05

Manufacturer Information

ROCHE SINGAPORE PTE. LTD.

Roche Diagnostics GmbH

Active Ingredients

ATEZOLIZUMAB

1875 mg/15ml

Atezolizumab

Documents

Package Inserts

Tecentriq PI.pdf

Approved: June 27, 2024

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

TECENTRIQ SOLUTION FOR INJECTION 1875MG/15ML - HSA Approval | MedPath